SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial

Peer Review reports

Original Submission
12 Jan 2016	Submitted	Original manuscript
9 May 2016	Reviewed	Reviewer Report - Brian Van Tine
23 Jun 2016	Reviewed	Reviewer Report - Eddy Pasquier
22 Jul 2016	Author responded	Author comments - Christoph Rochlitz
Resubmission - Version 2
22 Jul 2016	Submitted	Manuscript version 2
27 Aug 2016	Author responded	Author comments - Christoph Rochlitz
Resubmission - Version 3
27 Aug 2016	Submitted	Manuscript version 3
5 Sep 2016	Author responded	Author comments - Christoph Rochlitz
Resubmission - Version 4
5 Sep 2016	Submitted	Manuscript version 4
Publishing
29 Sep 2016	Editorially accepted
10 Oct 2016	Article published	10.1186/s12885-016-2823-y

Back to article page